
A corporate lawyer walked into a spirulina lab and stayed. At Lumen Bioscience, Brian Finrow is testing whether cheaper manufacturing can change not only how biologic drugs are made, but which problems the industry chooses to solve.
Lumen survived a biofuel bust and a pigment-price collapse by turning stubborn green microbes into miniature drug factories. Now its oral biologics face the test that matters: whether an elegant manufacturing trick can survive large clinical trials and the economics of medicine.